CTFA supports FDA's MedWatch in lieu of cosmetics adverse reporting program.
This article was originally published in The Rose Sheet
Executive Summary
FDA MEDWATCH SHOULD "EXPLICITLY INCLUDE" COSMETICS, CTFA recommends in comments on FDA's proposed elimination of the Voluntary Cosmetic Product Experience program. Filed Oct. 10, the Cosmetic, Toiletry and Fragrance Association comments propose that the MedWatch adverse reaction reporting program's reporting form and instructions "be recast explicitly to include cosmetic products." The MedWatch program was designed to cover adverse reaction reporting for all FDA-regulated products, but the reporting form "refers only to `medications' and `medical devices," CTFA notes.